Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Transgenic mouse model to address heterogeneity in autism spectrum disorders  

Rare, functional gene variants that lead to hyperfunction of the serotonin transporter (SERT) have been associated with a specific subset of autism spectrum traits, rigid-compulsive behaviors and sensory aversion. A novel, transgenic mouse model expressing the most common of these SERT variants, Ala56, has been produced. Based on preliminary evidence that mice expressing Ala56 SERT exhibit multiple behavioral and biochemical phenotypes, this project will extend studies and dissect the impact of SERT hyperfunction in these animals. These studies will enhance understanding of the contributions of altered SERT activity and regulation to autism heterogeneity and provide a novel platform for the preclinical evaluation of therapeutic interventions. Project Status
ONGOING

2010

Funder National Institutes of Health
Fiscal Year Funding $468,586.00
Current Award Period 2009-2011
Project Number 5R01HD065278-02
Principal Investigator Blakely, Randy
Received ARRA Funding? Yes
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Treatments)
Subcategory Model Systems/Therapeutic Targets
Strategic Plan Objective Green dot: Objective has greater than or equal to the recommended funding. 4SB. Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.
Federal or Private? Federal
Institution Vanderbilt University
State/Country Tennessee
Web Link 1 Transgenic mouse model to address heterogeneity in autism spectrum disorders (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
New! History/Related Projects Transgenic mouse model to address heterogeneity in autism spectrum disorders | $454,745.00 | 2009 | 1R01HD065278-01